

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number  
**WO 02/05836 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 38/00**
- (74) Agents: **ELMORE, Carolyn, S. et al.**; Hamilton, Brook, Smith & Reynolds, P.C., 530 Virginia Road,, P.O. Box 9133,, Concord, MA 01742-9133 (US).
- (21) International Application Number: **PCT/US01/22641**
- (22) International Filing Date: **18 July 2001 (18.07.2001)**
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**60/219,300** **19 July 2000 (19.07.2000)** **US**
- (71) Applicant (*for all designated States except US*): **THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS [US/US];** 201 West 7th Street, Austin, TX 78701 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **CARNEY, Darrell, H. [US/US];** 5020 Cedar Creek, Dickinson, TX 77539 (US). **CROWTHER, Roger, S. [US/US];** 1118 Downing Circle, League City, TX 77573 (US). **SIMMONS, David, J. [US/US];** 665 South Skinker Boulevard, #8D, St. Louis, MO 63105 (US). **YANG, Jinping [CN/US];** 1414 Church Street, Galveston, TX 77550 (US). **REDIN, William, R. [US/US];** 505 Old Bayou Drive, Dickinson, TX 77539 (US).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 02/05836 A2**

(54) Title: **STIMULATION OF BONE GROWTH WITH THROMBIN PEPTIDE DERIVATIVES**

(57) Abstract: Disclosed is a method of stimulation bone growth at a site in a subject in need of osteoinduction. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site.

-1-

## STIMULATION OF BONE GROWTH WITH THROMBIN PEPTIDE DERIVATIVES

### GOVERNMENT SUPPORT

The invention was supported, in whole or in part, by grant 1 R43 AR45508-  
5 01 and 2 R44 AR45508-02 from the National Institutes of Health. The Government  
has certain rights in the invention.

### RELATED APPLICATIONS

This applications claims the benefit of US Provisional Application No.  
60/219,300, filed July 19, 2000, the entire teachings of which are incorporated  
10 herein by reference.

### BACKGROUND OF THE INVENTION

Mammalian bone tissue has a remarkable ability to regenerate and thereby  
repair injuries and other defects. For example, bone growth is generally sufficient to  
bring about full recovery from most simple and hairline fractures. Unfortunately,  
15 however, there are many injuries, defects or conditions where bone growth is  
inadequate to achieve an acceptable outcome. For example, bone regeneration  
generally does not occur throughout large voids or spaces. Therefore, fractures  
cannot heal unless the pieces are in close proximity. If a significant amount of bone  
tissue was lost as a result of the injury, the healing process may be incomplete,  
20 resulting in undesirable cosmetic and/or mechanical outcomes. This is often the case  
with non-union fractures or with bone injuries resulting from massive trauma. Tissue  
growth is also generally inadequate in voids and segmental gaps in bone caused, for  
example, by surgical removal of tumors or cysts. In other instances, it may be  
desirable to stimulate bone growth where bone is not normally found, i.e.,  
25 ectopically. Spine fusion to relieve lower back pain where two or more vertebrae are  
induced to fuse is one example of desirable ectopic bone formation. Currently, such

-2-

gaps or segmental defects require bone grafts for successful repair or gap filling. The development of effective bone graft substitutes would eliminate the need to harvest bone from a second surgical site for a graft procedure, thereby significantly reducing the discomfort experienced by the patient and risk of donor site healing

5 complications.

Compounds which stimulate or induce bone growth at sites where such growth would not normally occur if left untreated are said to be "osteoinductive". An osteoinductive compound would have great value as a drug to treat the conditions described above. A number of osteoinductive proteins have been

10 identified, isolated and expressed using recombinant technology. Examples include the bone morphogenic proteins (BMPs) disclosed in U.S Patent No. 5,902,705 in WO 95/16035. However, the use of recombinant proteins as therapeutic agents generally has a number of drawbacks, including the cost of manufacture, *in vivo* biodegradation and short shelf lives. Consequently, scientists are continuing to

15 search for new osteoinductive agents which do not have the aforementioned shortcomings.

#### SUMMARY OF THE INVENTION

It has now been found that compounds which activate the non-proteolytic thrombin receptor are osteoinductive. For example, the compound TP508, an agonist

20 of the non-proteolytic thrombin receptor, stimulates bone growth in segmental critical size defects created in the ulna of male New Zealand rabbits (Example 2). As shown by x-ray and confirmed by histology and mechanical testing, there was a significant increase in bone formation induced by TP508 at doses of 100 µg and 200 µg compared with untreated controls. Based on these results, novel methods of

25 stimulating bone growth in a subject and novel implantable pharmaceutical compositions are disclosed herein.

One embodiment of the present invention is a method of stimulating bone growth at a site in a subject in need of osteoinduction. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-

30 proteolytically activated thrombin receptor to the site.

Another embodiment of the present invention is a pharmaceutical composition comprising an implantable, biocompatible carrier and an agonist of the non-proteolytically activated thrombin receptor.

The method of the present invention is directed at stimulating bone growth in a subject and can be used at sites where bone growth would not occur, absent treatment with autologous bone grafts or administration of bone growth factors. The method involves the administration of agonists of the non-proteolytic thrombin receptor. Such agonists include small peptides having homology to the segment between amino acid 508 and 530 of human prothrombin. These small peptides are inexpensive to prepare in bulk quantities and are osteoinductive at low dose. In addition, their lyophilized form is stable for at least thirty months when stored at 5° C and at 60% relative humidity.

#### DETAILED DESCRIPTION OF THE INVENTION

“Osteoinduction” refers to stimulating bone growth at a site within a subject at which little or no bone growth would occur if the site were left untreated. Sites which could therapeutically benefit from the induction of bone growth are referred to as “in need of osteoinduction”. Examples include non-union fractures or other severe or massive bone trauma. It is noted that bone growth normally occurs at bone injuries such as simple or hairline fractures and well opposed complex fractures with minimal gaps without the need for further treatment. Such injuries are not considered to be “in need of osteoinduction”.

Simple fracture repair appears to be quite different from the induction of bone formation required to fill non-union fractures, segmental gaps or bone voids caused, for example, by removal of a bone tumor or cyst. These cases require bone grafting or induction of new bone growth generally employing some type of matrix or scaffolding to serve as a bone growth substitute. Induced bone growth can also be therapeutically beneficial at certain sites within a subject (referred to as “ectopic” sites) where bone tissue would not normally be found, such as a site in need of a bone graft or bone fusion. Fusions are commonly used to treat lower back pain by physically coupling one or more vertebrae to its neighbor. The bone created by such

a fusion is located at a site not normally occupied by bone tissue. Osteoinduction at these ectopic sites can act as a "graft substitute" whereby induced bone growth between the vertebrae takes the place of a graft and obviates the need for a second operation to harvest bone for the grafting procedure. Induction of bone growth is also needed for treating acquired and congenital craniofacial and other skeletal or dental anomalies (see e.g., Glowacki *et al.*, *Lancet* 1: 959 (1981)); performing dental and periodontal reconstructions where lost bone replacement or bone augmentation is required such as in a jaw bone; and supplementing alveolar bone loss resulting from periodontal disease to delay or prevent tooth loss (see e.g., Sigurdsson *et al.*, *J. Periodontol.*, 66: 511 (1995)).


Applicants have discovered that compounds which stimulate or activate the non-proteolytically activated thrombin receptor (hereinafter "NPAR") are osteoinductive. Such compounds are said to be NPAR agonists. NPAR is a high-affinity thrombin receptor present on the surface of most cells. This NPAR component is largely responsible for high-affinity binding of thrombin, proteolytically inactivated thrombin, and thrombin derived peptides to cells. NPAR appears to mediate a number of cellular signals that are initiated by thrombin independent of its proteolytic activity. An example of one such signal is the upregulation of annexin V and other molecules identified by subtractive hybridization (see Sower, *et. al.*, *Experimental Cell Research* 247:422 (1999)). NPAR is therefore characterized by its high affinity interaction with thrombin at cell surfaces and its activation by proteolytically inactive derivatives of thrombin and thrombin derived peptide agonists as described below. NPAR activation can be assayed based on the ability of molecules to stimulate cell proliferation when added to fibroblasts in the presence of submitogenic concentrations of thrombin or molecules that activate protein kinase C or compete with <sup>125</sup>I-thrombin for high affinity binding to thrombin receptors, as disclosed in US Patent Nos. 5,352,664 and 5,500,412 and in Glenn *et al.*, *J. Peptide Research* 1:65 (1988). NPAR is to be distinguished from other thrombin binding proteins and the cloned family of proteolytically-activated receptors for thrombin, including the receptors PAR1, PAR2, PAR3 and PAR4. PAR1 possesses a specific thrombin cleavage site that

allows thrombin cleavage to expose a new amino-terminus domain that acts as a tethered ligand folding back onto itself inducing its activation (see, Vu, *et al.*, *Cell*. 64:1057 (1991)). PAR2 has a similar mechanism for activation, but is principally activated by trypsin-like enzymes (see, Zhong, *et al.*, *J. Biol. Chem.* 267:16975 (1992)). PAR3 also has a similar mechanism of activation and appears to function as a second thrombin receptor in platelets (see, Ishihara, *et al.*, *Nature*. 386:502 (1997)). PAR4 has been detected in mouse megakaryocytes and studies suggest that it also functions in human platelets (see, Kahn, *et al.*, *Nature* 394:690 (1998)). In contrast with these PAR receptors, activation of NPAR requires no proteolytic cleavage.

Several lines of evidence indicate that NPAR is distinct from PAR receptors: (1) a population of cells has been isolated that express fully functional PAR1 receptors, but are non-responsive to thrombin due to a defect in the NPAR signal transduction pathway (see, Kim, *et al.*, *J. Cell. Physiol.* 160:573 (1994)); (2) neutrophils bind <sup>125</sup>I thrombin with high affinity and their chemotaxis is stimulated by proteolytically inactivated thrombin or NPAR agonists (see, Ramakrishnan and Carney, *Mol. Biol. Cell* 4:1993 (1993)), yet they do not express PAR1 (see Jenkins, *et al.*, *J. Cell Sci.* 108:3059 (1995)); (3) IIC9 fibroblasts over-express PAR1, but do not bind thrombin with high affinity (see, Kim, D. Ph.D. Dissertation. The University of Texas Medical Branch at Galveston, 1995; and Low, *et al.*, "Cancer Cells 3/Growth Factors and Transformation", Cold Spring Harbor Laboratory, New York); and (4) NPAR agonists have distinct effects on gene expression from those of the PAR receptor agonist peptides (see, Sower, *et al.*, *Experimental Cell Research* 247: 422 (1999)).

One example of an NPAR agonist is a thrombin peptide derivative, i.e., a polypeptide with no more than about fifty amino acids, preferably no more than about thirty amino acids and having sufficient homology to the fragment of human thrombin corresponding to prothrombin amino acids 508-530 (SEQ ID NO. 5) that the polypeptide activates NPAR. The thrombin peptide derivatives described herein preferably have between about 12 and 23 amino acids, more preferably between

about 19 and 23 amino acids. One example of a thrombin peptide derivative comprises a moiety represented by Structural Formula (I):



(I)

5 R is a serine esterase conserved domain. Serine esterases, e.g., trypsin, thrombin chymotrypsin and the like, have a region that is highly conserved. "Serine esterase conserved domain" refers to a polypeptide having the amino acid sequence of one of these conserved regions or is sufficiently homologous to one of these conserved regions such that the thrombin peptide derivative retains NPAR activating ability.

10 In one embodiment, the serine esterase conserved sequence has the amino acid sequence of SEQ ID NO. 1 (Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val) or a C-terminal truncated fragment of a polypeptide having the amino acid sequence of SEQ ID NO 1. It is understood, however, that zero, one, two or three amino acids in the serine esterase conserved sequence can differ from the corresponding amino acid in SEQ ID NO 1. Preferably, the amino acids in the serine esterase conserved  
15 sequence which differ from the corresponding amino acid in SEQ ID NO 1 are conservative substitutions, and are more preferably highly conservative substitutions. A "C-terminal truncated fragment" refers to a fragment remaining after removing an amino acid or block of amino acids from the C-terminus, said  
20 fragment having at least six and more preferably at least nine amino acids.

More preferably, the serine esterase conserved sequence has the amino acid sequence of SEQ ID NO 2 (Cys-X<sub>1</sub>-Gly-Asp-Ser-Gly-Gly-Pro-X<sub>2</sub>-Val; X<sub>1</sub> is Glu or Gln and X<sub>2</sub> is Phe, Met, Leu, His or Val) or a C-terminal truncated fragment thereof having at least six amino acids, preferably at least nine amino acids.

25 In a preferred embodiment, the thrombin peptide derivative comprises a serine esterase conserved sequence and a polypeptide having a more specific thrombin amino acid sequence Arg-Gly-Asp-Ala (SEQ ID NO 3). One example of a thrombin peptide derivative of this type comprises Arg-Gly-Asp-Ala-Cys-X<sub>1</sub>-Gly-Asp-Ser-Gly-Gly-Pro-X<sub>2</sub>-Val (SEQ ID NO 4). X<sub>1</sub> and X<sub>2</sub> are as defined above.

30 When the thrombin peptide derivative comprises SEQ ID NO 4, it preferably has the

amino acid sequence of SEQ ID NO 5 (Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val) or an *N*-terminal truncated fragment thereof, provided that zero, one, two or three amino acids at positions 1-9 in the thrombin peptide derivative differ from the amino acid at the corresponding position of SEQ ID NO 5. Preferably, the amino acids in the thrombin peptide derivative which differ from the corresponding amino acid in SEQ ID NO 5 are conservative substitutions, and are more preferably highly conservative substitutions. An "*N*-terminal truncated fragment" refers to a fragment remaining after removing an amino acid or block of amino acids from the *N*-terminus, preferably a block of no more than six amino acids, more preferably a block of no more than three amino acids.

TP508 is an example of a thrombin peptide derivative and has the amino acid sequence of SEQ ID NO 5.

A "conservative substitution" is the replacement of an amino acid with another amino acid that has the same net electronic charge and approximately the same size and shape. Amino acids with aliphatic or substituted aliphatic amino acid side chains have approximately the same size when the total number carbon and heteroatoms in their side chains differs by no more than about four. They have approximately the same shape when the number of branches in the their side chains differs by no more than one. Amino acids with phenyl or substituted phenyl groups in their side chains are considered to have about the same size and shape. Listed below are five groups of amino acids. Replacing an amino acid in a polypeptide with another amino acid from the same group results in a conservative substitution:

Group I: glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, and non-naturally occurring amino acids with C1-C4 aliphatic or C1-C4 hydroxyl substituted aliphatic side chains (straight chained or monobranched).

Group II: glutamic acid, aspartic acid and non-naturally occurring amino acids with carboxylic acid substituted C1-C4 aliphatic side chains (unbranched or one branch point).

Group III: lysine, ornithine, arginine and non-naturally occurring amino acids with amine or guanidino substituted C1-C4 aliphatic side chains (unbranched or one branch point).



Group IV: glutamine, asparagine and non-naturally occurring amino acids with amide substituted C1-C4 aliphatic side chains (unbranched or one branch point).

Group V: phenylalanine, phenylglycine, tyrosine and tryptophan.

5           A "highly conservative substitution" is the replacement of an amino acid with another amino acid that has the same functional group in the side chain and nearly the same size and shape. Amino acids with aliphatic or substituted aliphatic amino acid side chains have nearly the same size when the total number carbon and heteroatoms in their side chains differs by no more than two. They have nearly the  
10   same shape when they have the same number of branches in the their side chains. Example of highly conservative substitutions include valine for leucine, threonine for serine, aspartic acid for glutamic acid and phenylglycine for phenylalanine. Examples of substitutions which are not highly conservative include alanine for valine, alanine for serine and aspartic acid for serine.

15           Other NPAR agonists include small organic molecules which bind and activate NPAR. Agonists of this type can be conveniently identified with high through-put screening, e.g., with assays that assess the ability of molecules to stimulate cell proliferation when added to fibroblasts in the presence of submitogenic concentrations of thrombin or molecules that activate protein kinase C  
20   as disclosed in US Patent Nos. 5,352,664 and 5,500,412. The entire teachings for US Patent Nos. 5,352,664 and 5,500,412 are incorporated herein by reference.

          The term "NPAR agonist" also includes compounds and combinations of compounds known to activate NPAR. Examples are disclosed in US Patent Nos. 5,352,664 and 5,500,412 and include the combination of DIP-alpha-thrombin with  
25   phorbol myristate acetate.

          An implantable biocompatible carrier for use in the pharmaceutical compositions described herein functions as a suitable delivery or support system for the NPAR agonist. A biocompatible carrier should be non-toxic, non-inflammatory, non-immunogenic and devoid of other undesired reactions at the implantation site.  
30   Suitable carriers also provide for release of the active ingredient and preferably for a

slow, sustained release over time at the implantation site.

Suitable carriers include porous matrices into which bone progenitor cells may migrate. Osteogenic cells can often attach to such porous matrices, which can then serve as a scaffolding for bone and tissue growth. For certain applications, the carrier should have sufficient mechanical strength to maintain its three dimensional structure and help support the immobilization of the bone segments being united or grafted together. Porous matrices which provide scaffolding for tissue growth can accelerate the rate of bone growth and are said to be "osteconductive". Osteoconductive carriers are highly preferred for use in the pharmaceutical compositions described herein.


Examples of suitable osteoconductive carriers include collagen (e.g., bovine dermal collagen), fibrin, calcium phosphate ceramics (e.g., hydroxyapatite and tricalcium phosphate), calcium sulfate, guanidine-extracted allogenic bone and combinations thereof. A number of suitable carriers are commercially available, such as COLLOGRAFT (Collagen Corporation, Palo Alto, CA), which is a mixture of hydroxyapatite, tricalcium phosphate and fibrillar collagen, and INTERPORE (Interpore International, Irvine CA), which is a hydroxyapatite biomatrix formed by the conversion of marine coral calcium carbonate to crystalline hydroxyapatite.

A number of synthetic biodegradable polymers can serve as osteoconductive carriers with sustained release characteristics. Descriptions of these polymers can be found in Behravesch *et al.*, *Clinical Orthopaedics* 367:S118 (1999) and Lichun *et al.*, *Polymeric Delivery Vehicles for Bone Growth Factors* in "Controlled Drug Delivery - Designing Technologies for the Future" Park and Mersny eds., American Chemical Society, Washington, DC (2000). The entire teachings of these references are incorporated herein by reference. Examples of these polymers include poly  $\alpha$ -hydroxy esters such as polylactic acid/polyglycolic acid homopolymers and copolymers, polyphosphazenes (PPHOS), polyanhydrides and poly(propylene fumarates).

Polylactic acid/polyglycolic acid (PLGA) homo and copolymers are well known in the art as sustained release vehicles. The rate of release can be adjusted by the skilled artisan by variation of polylactic acid to polyglycolic acid ratio and the

molecular weight of the polymer (see Anderson, *et al.*, *Adv. Drug Deliv. Rev.* 28:5 (1997), the entire teachings of which are incorporated herein by reference). The incorporation of poly(ethylene glycol) into the polymer as a blend to form microparticle carriers allows further alteration of the release profile of the active ingredient (see Cleek *et al.*, *J. Control Release* 48:259 (1997), the entire teachings of which are incorporated herein by reference). Ceramics such as calcium phosphate and hydroxyapatite can also be incorporated into the formulation to improve mechanical qualities.

PPHOS polymers contain alternating nitrogen and phosphorous with no carbon in the polymer backbone, as shown below in Structural Formula (II):




(II)

The properties of the polymer can be adjusted by suitable variation of side groups R and R' that are bonded to the polymer backbone. For example, the degradation of and drug release by PPHOS can be controlled by varying the amount of hydrolytically unstable side groups. With greater incorporation of either imidazolyl or ethylglycol substituted PPHOS, for example, an increase in degradation rate is observed (see Laurencin *et al.*, *J Biomed Mater. Res.* 27:963 (1993), the entire teachings of which are incorporated herein by reference), thereby increasing the rate of drug release.

Polyanhydrides, shown in Structural Formula (III), have well defined degradation and release characteristics that can be controlled by including varying amounts of hydrophobic or hydrophilic monomers such as sebacic acid and 1,3-bis(p-carboxyphenoxy)propane (see Leong *et al.*, *J. Biomed. Mater. Res.* 19:941 (1985), the entire teachings of which are incorporated herein by reference). To

improve mechanical strength, anhydrides are often copolymerized with imides to form polyanhydride-co-imides. Examples of polyanhydride-co-imides that are suitable for orthopaedic applications are poly(trimellitylimido-glycine-co-1,6-bis(carboxyphenoxy)hexane and pyromellitylimidoalanine:1,6-bis(p-carboxyphenoxy)hexane copolymers.



(III)

Poly(propylene fumarates) (PPF) are highly desirable biocompatible implantable carriers because they are an injectable, *in situ* polymerizable, biodegradable material. "Injectable" means that the material can be injected by syringe through a standard needle used for injecting pastes and gels. PPF, combined with a vinyl monomer (*N*-vinyl pyrrolidinone) and an initiator (benzoyl peroxide), forms an injectable solution that can be polymerized *in situ*. It is particularly suited for filling skeletal defects of a wide variety of sizes and shapes (see Suggs *et al.*, *Macromolecules* 30:4318 (1997), Peter *et al.*, *J. Biomater. Sci. Poly., Ed. 10*:363 (1999) and Yaszemski *et al.*, *Tissue Eng.* 1:41 (1995), the entire teachings of which are incorporated herein by reference). The addition of solid phase components such as  $\beta$ -tricalcium phosphate and sodium chloride can improve the mechanical properties of PPF polymers (see Peter *et al.*, *J. Biomed. Mater. Res.* 44:314 (1999), the entire teachings of which are incorporated herein by reference).

The pharmaceutical compositions of the present invention can be administered by implantation at a site in need of osteoinduction. "Implantation" or "administration at a site" means in sufficient proximity to the site in need of treatment so that osteoinduction occurs (e.g., bone growth in the presence of the

-12-

NPAR agonist but little or no growth in its absence) at the site when the NPAR agonist is released from the pharmaceutical composition.

The pharmaceutical compositions can be shaped as desired in anticipation of surgery or shaped by the physician or technician during surgery. It is preferred to shape the matrix to span a tissue defect and to take the desired form of the new tissue. In the case of bone repair of a non-union defect, for example, it is desirable to use dimensions that span the non-union. In bone formation procedures, the material is slowly absorbed by the body and is replaced by bone in the shape of or very nearly the shape of the implant. Alternatively, the pharmaceutical compositions can be administered to the site in the form of microparticles or microspheres. The microparticles are placed in contact or in close proximity to the site in need of osteoinduction either by surgically exposing the site and applying the microparticles on or in close proximity to the site by painting, pipetting, spraying, injecting or the like. Microparticles can also be delivered to the site by endoscopy or by laparoscopy. The preparation of PLGA microparticles and their use to stimulate bone growth are described in Examples 1 and 2.

In yet another alternative, the pharmaceutical composition can be partially enclosed in a supporting physical structure such as a mesh, wire matrix, stainless steel cage, threaded interbody fusion cage and the like before administering to the site in need of osteoinduction.

Another alternative for applying the pharmaceutical composition of the present invention is by injection. Compositions which are injectable include the solutions of poly(propylene fumarate) copolymers described above and pastes of calcium phosphate ceramics (see Schmitz *et al.*, *J. Oral Maxillofacial Surgery* 57:1122 (1999), the entire teachings of which are incorporated herein by reference). Injectable compositions can be injected directly to the site in need of osteoinduction and can conveniently be used to fill voids and fuse bones without the need for invasive surgery.

NPAR agonists can also be administered by means other than implantation, for example, by applying a solution comprising the NPAR agonist in an acceptable pharmaceutical carrier directly to or in near proximity to the site. Administration of a

solution can be conveniently accomplished, for example, by syringe, either through a surgical opening or by parenteral administration to the desired site. Standard pharmaceutical formulation techniques may be employed such as those described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA.

5 Suitable pharmaceutical carriers for parenteral administration include, for example, sterile water, physiological saline, bacteriostatic saline (saline containing about 0.9% mg/ml benzyl alcohol), phosphate-buffered saline, Hank's solution, Ringer's-lactate and the like.

A "therapeutically effective amount" is the quantity of NPAR agonist which  
10 results in bone growth where little or no bone growth would occur in the absence of the agonist. Typically, the agonist is administered for a sufficient period of time to achieve the desired therapeutic or cosmetic effect, i.e., sufficient bone growth. The amount administered will depend on the amount of bone growth that is desired, the health, size, weight, age and sex of the subject and the release characteristics of the  
15 pharmaceutical formulation. Typically, between about 1  $\mu$ g per day and about 1 mg per day of NPAR agonist (preferably between about 5  $\mu$ g per day and about 100  $\mu$ g per day) is administered by continuous release or by direct application to the site in need of bone growth.

A NPAR agonist or an implantable pharmaceutical composition of the  
20 present invention can be used in conjunction with an implantable prosthetic device. For example, a therapeutically effective amount of the pharmaceutical composition can be disposed on the prosthetic implant on a surface region that is implantable adjacent to a site in need of osteoinduction. Alternatively, the prosthetic device is constructed so as to continuously release the implantable pharmaceutical  
25 composition or NPAR agonist at a pre-determined rate. The prosthesis may be made from a material comprising metal or ceramic. Examples of prosthetic devices include a hip device, a screw, a rod and a titanium cage for spine fusion.

Thus this invention also provides a method for stimulating bone growth by implanting a prosthetic device into a site in need of osteoinduction in a subject. The  
30 prosthetic is at least partially coated with an implantable pharmaceutical composition described hereinabove and implanted at a site in need of osteoinduction

-14-

and maintained at the site for a period of time sufficient to permit stimulation of bone growth.

A "subject" is preferably a human, but can also be an animal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like).

Thrombin peptide derivatives can be synthesized by solid phase peptide synthesis (e.g., BOC or FMOC) method, by solution phase synthesis, or by other suitable techniques including combinations of the foregoing methods. The BOC and FMOC methods, which are established and widely used, are described in Merrifield, *J. Am. Chem. Soc.* 88:2149 (1963); Meienhofer, *Hormonal Proteins and Peptides*, C.H. Li, Ed., Academic Press, 1983, pp. 48-267; and Barany and Merrifield, in *The Peptides*, E. Gross and J. Meienhofer, Eds., Academic Press, New York, 1980, pp. 3-285. Methods of solid phase peptide synthesis are described in Merrifield, R.B., *Science*, 232: 341 (1986); Carpino, L.A. and Han, G.Y., *J. Org. Chem.*, 37: 3404 (1972); and Gauspohl, H. *et al.*, *Synthesis*, 5: 315 (1992)). The teachings of these six articles are incorporated herein by reference in their entirety.

The invention is illustrated by the following examples which are not intended to be limiting in any way.

20

#### EXEMPLIFICATION

##### Example 1 - Preparation of Polylactic Acid/Polyglycolic Acid Copolymer Microspheres of TP508

A double emulsion technique was used to prepare microspheres of polylactic acid/polyglycolic acid copolymer (PLGA) containing TP508.

25 Briefly, the matrix components were dissolved in methylene chloride and TP508 was dissolved in water. The two were gradually mixed together while vortexing to form a water-in-oil (W/O) emulsion. Polyvinyl alcohol (0.3% in water) was added to the emulsion with further vortexing to form the second emulsion (O/W), thereby forming a double emulsion: an O/W

emulsion comprised of PLGA droplets, and within those droplets, a second disperse phase consisting of TP508 in water. Upon phase separation, the PLGA droplets formed discrete microspheres containing cavities holding TP508. To cause phase separation of the microspheres, a 2% isopropyl alcohol solution was added. The particles were collected by centrifugation, and then lyophilized to remove residual moisture. The composition of the matrix was varied to form microspheres with different release kinetics (Table 1).

**Table 1:** Composition of different microsphere formulations

Formulation	PLGA	Polymer M. Wt.	% TP508	% poly-ethylene glycol
A	50:50	46,700	5	0
B	50:50	7,200	5	0
C	50:50	46,700	5	5
D	50:50	46,700	5	0
E	75:25	120,000	5	0

The mean diameter of the microspheres was measured in a Coulter counter and the drug entrapment efficiency was measured by spectrophotometric assay at 276 nm following dissolution of a weighed sample of microspheres in methylene chloride and extraction of the released drug into water (Table 2).

**Table 2:** Formulation diameter and drug entrapment efficiency

Formulation	Diameter, $\mu\text{m}$	TP508 Entrapment, %
A	26.0	53.8



-16-

B	16.2	27.1
C	17.6	58.9
D	23.9	42.6
E	25.8	36.2

5 To measure TP508 release from the different PLGA matrices, 20 mg of microspheres were placed in 1.0 ml of PBS contained in 1.5 ml polypropylene microcentrifuge tubes. Tubes were incubated at 37°C and shaken at 60 rpm. At various times, the tubes were centrifuged and the supernatant containing released TP508 was removed and frozen for

10 subsequent analysis. Fresh PBS was added to the microspheres and incubation was continued. TP508 in the supernatant was measured by absorbance at 276 nm. For each formulation, quadruplicate release determinations were performed. Formulations B and D showed no detectable drug release during 28 days of incubation at 37°C. The remaining

15 formulations all released detectable amounts of TP508, although in all cases the amount of drug released fell below detectable limits (<1 µg/mg matrix/day) within 3-4 days. Formulations A and C showed the greatest release of TP508, releasing 60-80% of the entrapped drug over 3-4 days. The formulation with the fastest release kinetics, C, was chosen for further

20 testing in *in vivo* studies.

Example 2 - PLGA Microspheres Containing TP508 Induce Bone Formation in Large (1.5 cm) Defects in Rabbit Ulna

A 1.5 cm segmental defect was created in each ulna of 20 male New Zealand rabbits. These bilateral ulnar osteotomies were created exactly the

25 same size by using a small metal guide to direct the cutting blade of the oscillating microsaw. Each rabbit acted as its own control; thus the left defect was filled with microspheres that did not contain TP508, while the right defect was filled with microspheres containing 100 or 200 µg TP508 (10 animals/group). The microspheres were prepared as described in

30 Example 1. Rabbits given bilateral ulnar osteotomies were randomly divided into two groups. The first group received 100 µg of TP508 in

microspheres (30 mg) in the right limb and microspheres alone in the left limb. The second group was treated similarly, but received 200 µg of TP508. These different doses were achieved by mixing TP508-containing and TP508-devoid microspheres in different proportions. Animals were x-rayed at two week intervals, beginning at week three, and sacrificed at nine weeks.

100 µg of TP508 stimulated mineralization in the defect at 3 and 5 weeks post-surgery. X-rays at 7 and 9 weeks appeared similar to those obtained at 5 weeks. Animals were sacrificed at 9 weeks post-surgery and the ulna-radius was removed and photographed. In most cases a large defect is still visible in ulnas from the control limbs, in contrast with the TP508-treated limbs, in which most of the defects have successfully closed.

After sacrifice at 9 weeks post-surgery, repair strength was measured by torsion testing (MTS-858 Minibionix machine). The results are shown in Tables 3 and 4.

**Table 3: Torsion testing of segmental defects treated with 100 µg TP508.**

Parameter	Control	SEM	TP508, 100 µg	SEM
Ultimate torque	0.107	0.034	0.255+	0.041
Failure torque	0.103	0.032	0.239+	0.042
Ultimate energy	0.815	0.365	1.916^	0.398
Failure energy	0.940	0.436	2.064^	0.421
Stiffness coeff.	0.013	0.004	0.028^	0.006

<sup>^</sup>*p* < 0.05, +*p* < 0.01

**Table 4: Torsion testing of segmental defects treated with 200 µg TP508.**

Parameter	Control	SEM	TP508, 200 µg	SEM
Ultimate torque	0.095	0.042	0.322*	0.046
Failure torque	0.093	0.041	0.306*	0.046
Ultimate energy	0.534	0.355	2.947*	0.543

-18-

Failure energy	0.641	0.374	3.433*	0.701
Stiffness coeff.	0.016	0.006	0.033^	0.004

 $^{\wedge}p < 0.05$ ,  $*p \leq 0.005$ 

- 5 At 100  $\mu$ g, TP508 more than doubled the mechanical strength of the healing defect as measured by all the parameters tested (Table 3). Even stronger repairs were noted in the 200- $\mu$ g group (Table 4), with most parameters being approximately 50% higher than those seen in the low dose treatment group.

In summation, ulnar osteotomies treated with microspheres containing the NPAR agonist TP508 showed evidence of bone mineralization and growth whereas in most control osteotomies that received osteoconductive microspheres, there was no bone growth and/or failure to fill the voided region. Mechanical testing for

5 mechanical strength and stiffness confirmed significant effects of TP508 on bone formation in this model. Because TP508 induced bone formation in sites where it did not occur without TP508, this discovery of osteoinduction is distinct from prior studies, in which TP508 accelerated the rate of normal fracture healing in fracture or small gap defects that would heal without TP508.

-20-

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

## CLAIMS

What is claimed is:

1. A method of stimulating bone growth at a site in a subject in need of osteoinduction, said method comprising the step of administering to the site a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor.
2. The method of Claim 1 wherein the site is in need of a bone graft.
3. The method of Claim 1 wherein the site is a segmental gap in a bone, a bone void or at a non-union fracture.
4. The method of Claim 1 wherein the agonist is a thrombin peptide derivative comprising a polypeptide represented by the following structural formula:



wherein R is a serine esterase conserved sequence.

5. The method of Claim 4 wherein the thrombin peptide derivative has between about 12 and about 23 amino acids.
6. The method of Claim 5 wherein the serine esterase conserved sequence has the amino acid sequence of SEQ ID NO. 1 (Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val), or a C-terminal truncated fragment thereof having at least six amino acids, provided that zero, one, two or three amino acids in the serine esterase conserved sequence differ from the corresponding position of SEQ ID NO 1.
7. The method of Claim 5 wherein the serine esterase conserved sequence has the amino acid sequence of SEQ ID NO. 1 (Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val), or a C-terminal truncated fragment thereof having at least nine amino acids, provided that zero, one or two of the amino acids in the serine

-22-

esterase conserved region are conservative substitutions of the corresponding amino acid in SEQ ID NO 1.

8. The method of Claim 5 wherein the serine esterase conserved sequence has the amino acid sequence of SEQ ID NO 2 (Cys-X<sub>1</sub>-Gly-Asp-Ser-Gly-Gly-Pro-X<sub>2</sub>-Val, wherein X<sub>1</sub> is Glu or Gln and X<sub>2</sub> is Phe, Met, Leu, His or Val),  
5 or a C-terminus truncated fragment of SEQ ID NO 2, said fragment having at least six amino acids.
9. The method of Claim 8 wherein the thrombin peptide derivative comprises the amino acid sequence Arg-Gly-Asp-Ala (SEQ ID NO 3).
- 10 10. The method of Claim 9 wherein the thrombin peptide derivative comprises the amino acid sequence Arg-Gly-Asp-Ala-Cys-X<sub>1</sub>-Gly-Asp-Ser-Gly-Gly-Pro-X<sub>2</sub>-Val (SEQ ID NO 4), wherein X<sub>1</sub> is Glu or Gln and X<sub>2</sub> is Phe, Met, Leu, His or Val.
11. The method of Claim 10 wherein the thrombin peptide derivative has the  
15 amino acid sequence Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val- (SEQ ID NO 5), or an N-terminal truncated fragment thereof, provided that zero, one, two or three amino acids at positions 1-9 in the thrombin peptide derivative differ from the amino acid at the corresponding position of SEQ ID NO 5.
- 20 12. The method of Claim 10 wherein the thrombin peptide derivative has the amino acid sequence Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val- (SEQ ID NO 5), or an N-terminal truncated fragment thereof, provided that zero, one or two amino  
25 acids at positions 1-9 in the thrombin peptide derivative are conservative substitutions of the amino acid at the corresponding position of SEQ ID NO 5.

13. The method of Claim 11 wherein the thrombin peptide derivative is administered in a pharmaceutical composition additionally comprising an implantable, biocompatible carrier.
14. The method of Claim 13 wherein the implantable, biocompatible carrier is an osteoconductive matrix.
15. The method of Claim 11 wherein the carrier comprises a polylactic acid/polyglycolic acid homopolymer or copolymer.
16. The method of Claim 1 wherein the subject is a farm animal, a companion animal or a laboratory animal.
17. A pharmaceutical composition comprising an implantable, biocompatible carrier and an agonist of the non-proteolytically activated thrombin receptor.
18. The pharmaceutical composition of Claim 17 wherein the carrier is osteoconductive.
19. The pharmaceutical composition of Claim 18 wherein the thrombin receptor agonist is thrombin peptide derivative comprises a polypeptide represented by the following structural formula:
- Asp-Ala-R;
- wherein R is a serine esterase conserved sequence.
20. The pharmaceutical composition of Claim 19 wherein the carrier is a biodegradable synthetic polymer.
21. The pharmaceutical composition of Claim 20 wherein the biodegradable synthetic polymer is a polylactic acid/polyglycolic acid homopolymer or copolymer.
22. The pharmaceutical composition of Claim 19 wherein the carrier comprises collagen, fibrin, calcium phosphate salts, calcium sulfate, guanidine-extracted allogenic bone or a combination thereof.



-24-

23. The pharmaceutical composition of Claim 19 wherein the carrier is injectable.
24. The pharmaceutical composition of Claim 23 wherein the carrier is a poly(propylene fumarate) solution or a calcium phosphate ceramic paste.
- 5 25. The pharmaceutical composition of Claim 19 wherein the pharmaceutical composition is administered as microparticles.
26. The pharmaceutical composition of Claim 19 wherein the pharmaceutical composition is pre-shaped before applying to the site in need of osteoinduction.
- 10 27. The pharmaceutical composition of Claim 19 wherein the thrombin peptide derivative has between about 12 and about 23 amino acids.
28. The pharmaceutical composition of Claim 27 wherein the serine esterase conserved sequence has the amino acid sequence of SEQ ID NO. 1 (Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val), or a C-terminal truncated fragment thereof having at least six amino acids, provided that zero, one, two or three amino acids in the serine esterase conserved sequence differ from the corresponding position of SEQ ID NO 1.
- 15 29. The pharmaceutical composition of Claim 27 wherein the serine esterase conserved sequence has the amino acid sequence of SEQ ID NO. 1 (Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val), or a C-terminal truncated fragment thereof having at least nine amino acids, provided that zero, one or two of the amino acids in the serine esterase conserved sequence are conservative substitutions of the corresponding amino acid in SEQ ID NO 1.
- 20 30. The pharmaceutical composition of Claim 27 wherein the serine esterase conserved sequence has the amino acid sequence of SEQ ID NO 2 (Cys-X<sub>1</sub>-Gly-Asp-Ser-Gly-Gly-Pro-X<sub>2</sub>-Val), wherein X<sub>1</sub> is Glu or Gln and X<sub>2</sub> is Phe, Met, Leu, His or Val), or a C-terminus truncated fragment of SEQ ID NO 2, said fragment having at least six amino acids.
- 25

31. The pharmaceutical composition of Claim 30 wherein the thrombin peptide derivative comprises the amino acid sequence Arg-Gly-Asp-Ala (SEQ ID NO 3).
32. The pharmaceutical composition of Claim 31 wherein the thrombin peptide derivative comprises the amino acid sequence Arg-Gly-Asp-Ala-Cys-X<sub>1</sub>-Gly-Asp-Ser-Gly-Gly-Pro-X<sub>2</sub>-Val (SEQ ID NO 4), wherein X<sub>1</sub> is Glu or Gln and X<sub>2</sub> is Phe, Met, Leu, His or Val.
33. The pharmaceutical composition of Claim 32 wherein the thrombin peptide derivative has the amino acid sequence Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val- (SEQ ID NO 5), or an *N*-terminal truncated fragment thereof, provided that zero, one, two or three amino acids at positions 1-9 in the thrombin peptide derivative differ from the amino acid at the corresponding position of SEQ ID NO 5.
34. The pharmaceutical composition of Claim 32 wherein the thrombin peptide derivative has the amino acid sequence Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val- (SEQ ID NO 5), or an *N*-terminal truncated fragment thereof, provided that zero, one or two amino acids at positions 1-9 in the thrombin peptide derivative are conservative substitutions of the amino acid at the corresponding position of SEQ ID NO 5.
35. A method of stimulating bone growth at a site in a subject in need of osteoinduction, said method comprising the step of administering to the site a therapeutically effective amount of a peptide having the sequence Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO 5).
36. A method of stimulating bone growth at a site in need of a bone graft in a subject, said method comprising the step of administering to the site a therapeutically effective amount of a peptide having the sequence Ala-Gly-

Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO 5).

37. A method of stimulating bone growth in a subject at a segmental bone gap, a bone void or a non-union fracture, said method comprising the step of  
5 administering to the bone gap, bone void or nonunion fracture a therapeutically effective amount of a peptide having the sequence Ala-Gly-  
Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO 5).

**THIS PAGE BLANK (USPTO)**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number  
**WO 02/005836 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 38/48**,  
A61L 27/12, 27/14, 27/46, 27/50, A61P 19/00

(74) Agents: **ELMORE, Carolyn, S. et al.**; Hamilton, Brook,  
Smith & Reynolds, P.C., 530 Virginia Road., P.O. Box  
9133,, Concord, MA 01742-9133 (US).

(21) International Application Number: PCT/US01/22641

(22) International Filing Date: 18 July 2001 (18.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/219,300 19 July 2000 (19.07.2000) US

(71) Applicant (*for all designated States except US*): **THE  
BOARD OF REGENTS, THE UNIVERSITY OF  
TEXAS SYSTEMS** [US/US]; 201 West 7th Street,  
Austin, TX 78701 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CARNEY, Darrell,**  
H. [US/US]; 5020 Cedar Creek, Dickinson, TX 77539  
(US). **CROWTHER, Roger, S.** [US/US]; 1118 Downing  
Circle, League City, TX 77573 (US). **SIMMONS, David,**  
J. [US/US]; 665 South Skinker Boulevard, #8D, St. Louis,  
MO 63105 (US). **YANG, Jinping** [CN/US]; 1414 Church  
Street, Galveston, TX 77550 (US). **REDIN, William, R.**  
[US/US]; 505 Old Bayou Drive, Dickinson, TX 77539  
(US).

Published:

— with international search report

(88) Date of publication of the international search report:  
19 December 2002

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*



**WO 02/005836 A3**

(54) Title: STIMULATION OF BONE GROWTH WITH THROMBIN PEPTIDE DERIVATIVES

(57) Abstract: Disclosed is a method of stimulation bone growth at a site in a subject in need of osteoinduction. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site.

## INTERNATIONAL SEARCH REPORT

national Application No

PCT/US 01/22641

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/48 A61L27/12 A61L27/14 A61L27/46 A61L27/50  
A61P19/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 88 03151 A (UNIV TEXAS) 5 May 1988 (1988-05-05) cited in the application page 7, line 4 -page 9, line 21; claims 1-12,25-29; example 7A	1-37
A	L.E. SOWER ET AL.: "Thrombin peptide, TP508, induces differential gene expression in fibroblasts through a nonproteolytic activation pathway." EXPERIMENTAL CELL RESEARCH, vol. 247, no. 2, 15 March 1999 (1999-03-15), pages 422-431, XP002202071 cited in the application page 422, left-hand column	1-37

-/--



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

13 June 2002

Date of mailing of the international search report

28/06/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Ryckebosch, A

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/22641

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 563 489 A (URIST MARSHALL R) 7 January 1986 (1986-01-07) claims -----	1-37

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/22641**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 1-16 and 35-37 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

ational Application No

PCT/US 01/22641

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 8803151	A	05-05-1988	US 5352664 A AT 105842 T AU 8239987 A DE 3789870 D1 DE 3789870 T2 EP 0328552 A1 JP 2501028 T JP 3054150 B2 US 5500412 A WO 8803151 A2	04-10-1994 15-06-1994 25-05-1988 23-06-1994 01-09-1994 23-08-1989 12-04-1990 19-06-2000 19-03-1996 05-05-1988
US 4563489	A	07-01-1986	NONE	

**THIS PAGE BLANK (USPTO)**